Developer docs
API playgroundTry for free, no card

Search company profiles

Spore.Bio

Full company profile

uuid0000k5z

Namestring
Spore.Bio
Legal namestring
Spore Biotechnologies SAS
Websiteurl
spore.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Spore.Bio (legal entity Spore Biotechnologies SAS) is a Paris-based deeptech company founded in 2023 that has developed Louis, a tabletop microbiological detection device powered by its proprietary Transformer-Based Multimodal Spectral Imaging (TMSI) platform. The device detects, quantifies, and identifies living microorganisms in under 10 minutes by analyzing intrinsic fluorescence signals triggered via dual-wavelength illumination, eliminating the need for culture, enrichment, stains, or reagents. The company targets quality control and contamination management in food & beverage, cosmetics, and pharmaceutical manufacturing, with secondary positioning in water/environment monitoring and cell/gene therapy sterility testing.

The technology stack combines biophotonic hardware with a Transformer-based foundational AI model trained on millions of fields of view across diverse matrices and stress conditions, supported by NVIDIA compute infrastructure and research collaborations with Institut Pasteur and DeepMind. The commercial platform includes the Louis instrument, proprietary single-use consumables (high-precision capture modules), and a cloud dashboard providing 21 CFR Part 11 compliant data management with audit trails for regulated environments.

Spore.Bio operates a sales-led enterprise field sales motion with direct engagement, pilot programs, and multi-year contracts targeting QC Directors, Food Safety Managers, and C-suite buyers at large manufacturers. Revenue streams are hardware sales (Louis devices), recurring consumables, and a cloud data subscription. The company is headquartered in Paris with a US commercial team being built in New York, has raised approximately $35M (€29.9M) across a 2023 pre-seed led by LocalGlobe, a February 2025 Series A led by Singular, and a January 2026 Google.org AI for Science grant, and acquired spectral-data-science firm GreenTropism in February 2025. The team of 58 spans 18 nationalities with backgrounds in photonics, AI, and biology.

Short descriptiontext

Spore.Bio (Spore Biotechnologies SAS) develops Louis, an AI-based microbiological detection device using proprietary TMSI spectral imaging technology. The Paris-based deeptech firm performs reagent-free microbial detection in under 10 minutes for food and beverage, cosmetics, and pharmaceutical manufacturers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid microbiology testing, AI microbial detection, quality control instruments, pathogen detection devices, contamination monitoring
Industry3 codes
PRIMARYHLAAALAG
Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAJAK
Quality Control (QC) Testing Technologies for Biomanufacturing (release/stability assays, rapid microbiology)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Industrial Instruments For Measurement, Display, And Control3823
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Microbiology Testing Instruments
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Louis Device Sales
TypeHardware Sales
Description

Sale of the Louis microbiological testing device - the world's first AI-based microbiological instrument for real-time pathogen detection in factories.

spore.bio
2Proprietary Consumables
TypeSubscription Recurring
Description

Recurring revenue from single-use consumables (proprietary filters/capture modules) required for each test run on the Louis device.

spore.bio
3Cloud Dashboard & Data Services
TypeSubscription Recurring
Description

Cloud-based microbial data dashboard providing real-time process improvement insights, trend tracking across sites, and 21 CFR Part 11 compliant data management.

spore.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Pricing details2 tiers
1Enterprise enterprise agreements
ModelOtherBilling cadenceAnnual
Notes

Custom pricing for enterprise customers based on deployment scale, number of devices, testing volume, and contract length. Contact-based pricing through sales team.

spore.bio
2Discovery call for pilot programs
ModelOtherBilling cadenceMulti-year contract
Notes

Companies can request discovery calls and pilot programs. No self-serve pricing available.

spore.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Spore.Labs
Description

AI-native research division launched in January 2026 focused on public health challenges using photonics and AI for microbiology testing.

eu-startups.com
Core offering1 text field

Spore.Bio sells the Louis device, an AI-based microbiological detection instrument that detects, quantifies, and identifies living microorganisms in under 10 minutes without culture, enrichment, or dyes. The platform combines proprietary dual-wavelength illumination with a Transformer-based AI model to deliver reagent-free microbial testing for factory floors, supported by recurring single-use consumables and a 21 CFR Part 11 compliant cloud dashboard.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Detection time reduced from 20 days to 10 minutes
+4 more records
Product overview1 text field

Spore.Bio's product portfolio centers on Louis, the world's first AI-based microbiological detection device — a tabletop instrument built on the proprietary TMSI (Transformer-Based Multimodal Spectral Imaging) platform. Louis performs reagent-free, culture-free microbial detection, quantification, and identification in under 10 minutes by analyzing intrinsic fluorescence signals via a Transformer-based AI model. The platform targets quality control in food & beverage, cosmetics, pharmaceutical, and other manufacturing environments, replacing slow traditional culture methods with real-time monitoring. A cloud-connected dashboard enables data traceability, trend analysis, and cross-site oversight. The portfolio also includes Spore.Labs, an AI-native research division focused on public health applications including antimicrobial resistance (AMR) and microbiome research.

Product and service4 records
1Louis
CategoryMicrobiology Testing Instruments
Description

The Louis device is the world's first AI-based microbiological detection instrument, a tabletop hardware device that detects, quantifies, and identifies living microorganisms in under 10 minutes. It uses label-free, reagent-free spectral imaging to replace slow culture-based methods with real-time quality control for factory floors in food & beverage, cosmetics, and pharmaceutical manufacturing.

2TMSI (Transformer-Based Multimodal Spectral Imaging)
CategoryCore Technology Platform
Description

TMSI is the underlying technology platform powering Louis, combining dual-wavelength illumination that triggers intrinsic fluorescence with a Transformer-based AI model that analyzes multi-spectral signals and spatial context. It detects and identifies microorganisms without culture, enrichment, or dyes, delivering results in under 10 minutes for industrial quality control applications.

3Proprietary Consumables
CategoryConsumables
Description

Single-use, ready-to-use proprietary filters/capture modules required for each test run on the Louis device. Designed to handle samples from purified water to complex beverages without clogging, and requiring no growth media or reagents.

4Cloud Dashboard and Data Services
CategorySoftware Services
Description

A cloud-based microbial data dashboard providing real-time process improvement insights, trend tracking across sites, and 21 CFR Part 11 compliant data management with secure access and audit trails. Delivered alongside the Louis device for continuous quality monitoring.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development Partner
Description

World-renowned microbiology research institution partnering with Spore.Bio for scientific collaboration and validation of detection technology.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

AI research powerhouse backing Spore.Bio's technology development in the application of machine learning to microbiology.

Strategic tierMajorTypeTechnology or Integration
Description

GPU and AI computing infrastructure partner providing hardware support for training AI models and computational requirements.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

World's largest startup campus in Paris providing infrastructure and ecosystem support.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in industrial and clinical microbiology, with deep installed base of microbial detection instruments (e.g., TEMPO, VITEK) in food, pharma, and cosmetics QC labs. Direct overlap with Spore.Bio's industrial QC use cases across all three target verticals.

TypeDirect peer
Description

Specializes in rapid microbiology and ATP hygiene monitoring for food safety and beverage manufacturing — direct overlap with Spore.Bio's food & beverage and environmental monitoring use cases.

TypeBroad incumbent
Description

Food and animal safety testing company (merged with 3M Food Safety in 2022), offering rapid pathogen detection kits and instruments. Overlaps with Spore.Bio in food safety QC workflows.

TypeBroad incumbent
Description

Major life sciences and diagnostics company with established industrial microbiology and sterility testing products serving pharma manufacturers — competes with Spore.Bio in pharmaceutical QC and batch release.

5Merck KGaA (MilliporeSigma)
TypeBroad incumbent
Description

Provides a comprehensive portfolio of microbiology testing products, consumables, and rapid sterility solutions for pharmaceutical and food manufacturers — directly competes with Louis in pharma GMP labs.

TypeBroad incumbent
Description

Global life sciences instruments giant offering a wide range of microbiology, cell culture, and analytical instruments. Overlaps with Spore.Bio's analytical instrument positioning in pharma and food QC.

TypeDirect peer
Description

Mid-cap German diagnostics company specializing in food and feed safety testing, including rapid microbiology and PCR-based pathogen detection — direct overlap in industrial food QC workflows.

TypeEmerging player
Description

AI-driven food safety testing company using next-generation sequencing for pathogen detection in food production. Closest emerging competitor applying AI/computational biology to industrial microbial testing.

TypeOthers
Description

World's largest food and pharmaceutical testing services network, operating centralized labs that perform conventional microbiology for manufacturers. Could be both a competitor (service-based testing) and a partner/distribution channel for Spore.Bio.

TypeBroad incumbent
Description

Established life science and clinical diagnostics company with a real-time PCR and digital PCR portfolio widely used for microbial detection in food, water, and pharma QC — competes with Louis's speed advantage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spore.Bio

Microbiology Testing Instrumentsspore.bio

Spore.Bio (Spore Biotechnologies SAS) develops Louis, an AI-based microbiological detection device using proprietary TMSI spectral imaging technology. The Paris-based deeptech firm performs reagent-free microbial detection in under 10 minutes for food and beverage, cosmetics, and pharmaceutical manufacturers.

What Spore.Bio does

Spore.Bio (legal entity Spore Biotechnologies SAS) is a Paris-based deeptech company founded in 2023 that has developed Louis, a tabletop microbiological detection device powered by its proprietary Transformer-Based Multimodal Spectral Imaging (TMSI) platform. The device detects, quantifies, and identifies living microorganisms in under 10 minutes by analyzing intrinsic fluorescence signals triggered via dual-wavelength illumination, eliminating the need for culture, enrichment, stains, or reagents. The company targets quality control and contamination management in food & beverage, cosmetics, and pharmaceutical manufacturing, with secondary positioning in water/environment monitoring and cell/gene therapy sterility testing.

The technology stack combines biophotonic hardware with a Transformer-based foundational AI model trained on millions of fields of view across diverse matrices and stress conditions, supported by NVIDIA compute infrastructure and research collaborations with Institut Pasteur and DeepMind. The commercial platform includes the Louis instrument, proprietary single-use consumables (high-precision capture modules), and a cloud dashboard providing 21 CFR Part 11 compliant data management with audit trails for regulated environments.

Spore.Bio operates a sales-led enterprise field sales motion with direct engagement, pilot programs, and multi-year contracts targeting QC Directors, Food Safety Managers, and C-suite buyers at large manufacturers. Revenue streams are hardware sales (Louis devices), recurring consumables, and a cloud data subscription. The company is headquartered in Paris with a US commercial team being built in New York, has raised approximately $35M (€29.9M) across a 2023 pre-seed led by LocalGlobe, a February 2025 Series A led by Singular, and a January 2026 Google.org AI for Science grant, and acquired spectral-data-science firm GreenTropism in February 2025. The team of 58 spans 18 nationalities with backgrounds in photonics, AI, and biology.

Spore.Bio firmographics

Firmographics
Name
Spore.Bio
Legal name
Spore Biotechnologies SAS
Website
https://spore.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
51–100 employees
Short description
Spore.Bio (Spore Biotechnologies SAS) develops Louis, an AI-based microbiological detection device using proprietary TMSI spectral imaging technology. The Paris-based deeptech firm performs reagent-free microbial detection in under 10 minutes for food and beverage, cosmetics, and pharmaceutical manufacturers.
Ownership category
akta.pro rank

Spore.Bio industry classification

Industry
Product category
Microbiology Testing Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Industrial Instruments For Measurement, Display, And Control (3823), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAG
Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow)
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAAAJAK
Quality Control (QC) Testing Technologies for Biomanufacturing (release/stability assays, rapid microbiology)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Rapid microbiology testing
  • AI microbial detection
  • Quality control instruments
  • Pathogen detection devices
  • Contamination monitoring

Where Spore.Bio is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Spore.Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Louis Device Sales: Sale of the Louis microbiological testing device - the world's first AI-based microbiological instrument for real-time pathogen detection in factories.
  2. Proprietary Consumables: Recurring revenue from single-use consumables (proprietary filters/capture modules) required for each test run on the Louis device.
  3. Cloud Dashboard & Data Services: Cloud-based microbial data dashboard providing real-time process improvement insights, trend tracking across sites, and 21 CFR Part 11 compliant data management.

Pricing tiers

ModelBillingPrice
OtherAnnualEnterprise enterprise agreements
OtherMulti-year contractDiscovery call for pilot programs

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Spore.Bio product offering

Product offering

Core offering

Spore.Bio sells the Louis device, an AI-based microbiological detection instrument that detects, quantifies, and identifies living microorganisms in under 10 minutes without culture, enrichment, or dyes. The platform combines proprietary dual-wavelength illumination with a Transformer-based AI model to deliver reagent-free microbial testing for factory floors, supported by recurring single-use consumables and a 21 CFR Part 11 compliant cloud dashboard.

Product overview

Spore.Bio's product portfolio centers on Louis, the world's first AI-based microbiological detection device — a tabletop instrument built on the proprietary TMSI (Transformer-Based Multimodal Spectral Imaging) platform. Louis performs reagent-free, culture-free microbial detection, quantification, and identification in under 10 minutes by analyzing intrinsic fluorescence signals via a Transformer-based AI model. The platform targets quality control in food & beverage, cosmetics, pharmaceutical, and other manufacturing environments, replacing slow traditional culture methods with real-time monitoring. A cloud-connected dashboard enables data traceability, trend analysis, and cross-site oversight. The portfolio also includes Spore.Labs, an AI-native research division focused on public health applications including antimicrobial resistance (AMR) and microbiome research.

Differentiator

Problem solved

Functional benefit

Brands

  • Spore.Labs: AI-native research division launched in January 2026 focused on public health challenges using photonics and AI for microbiology testing.

Products and services

  • Louis The Louis device is the world's first AI-based microbiological detection instrument, a tabletop hardware device that detects, quantifies, and identifies living microorganisms in under 10 minutes. It uses label-free, reagent-free spectral imaging to replace slow culture-based methods with real-time quality control for factory floors in food & beverage, cosmetics, and pharmaceutical manufacturing.
  • TMSI (Transformer-Based Multimodal Spectral Imaging) TMSI is the underlying technology platform powering Louis, combining dual-wavelength illumination that triggers intrinsic fluorescence with a Transformer-based AI model that analyzes multi-spectral signals and spatial context. It detects and identifies microorganisms without culture, enrichment, or dyes, delivering results in under 10 minutes for industrial quality control applications.
  • Proprietary Consumables Single-use, ready-to-use proprietary filters/capture modules required for each test run on the Louis device. Designed to handle samples from purified water to complex beverages without clogging, and requiring no growth media or reagents.
  • Cloud Dashboard and Data Services A cloud-based microbial data dashboard providing real-time process improvement insights, trend tracking across sites, and 21 CFR Part 11 compliant data management with secure access and audit trails. Delivered alongside the Louis device for continuous quality monitoring.

Quantifiable outcome

  • Detection time reduced from 20 days to 10 minutes
  • +4 more outcomes

Companies that use Spore.Bio

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Spore.Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Spore.Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and minor.

  • Institut PasteurmajorStrategic or Co-development PartnerWorld-renowned microbiology research institution partnering with Spore.Bio for scientific collaboration and validation of detection technology.
  • DeepMindmajorStrategic or Co-development PartnerAI research powerhouse backing Spore.Bio's technology development in the application of machine learning to microbiology.
  • NVIDIAmajorTechnology or IntegrationGPU and AI computing infrastructure partner providing hardware support for training AI models and computational requirements.
  • STATION FminorStrategic or Co-development PartnerWorld's largest startup campus in Paris providing infrastructure and ecosystem support.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Spore.Bio competitors and assessment

Company assessment

Broad incumbents

  • bioMérieux: Global leader in industrial and clinical microbiology, with deep installed base of microbial detection instruments (e.g., TEMPO, VITEK) in food, pharma, and cosmetics QC labs. Direct overlap with Spore.Bio's industrial QC use cases across all three target verticals.
  • Neogen Corporation: Food and animal safety testing company (merged with 3M Food Safety in 2022), offering rapid pathogen detection kits and instruments. Overlaps with Spore.Bio in food safety QC workflows.
  • Becton Dickinson (BD): Major life sciences and diagnostics company with established industrial microbiology and sterility testing products serving pharma manufacturers — competes with Spore.Bio in pharmaceutical QC and batch release.
  • Merck KGaA (MilliporeSigma): Provides a comprehensive portfolio of microbiology testing products, consumables, and rapid sterility solutions for pharmaceutical and food manufacturers — directly competes with Louis in pharma GMP labs.
  • Thermo Fisher Scientific: Global life sciences instruments giant offering a wide range of microbiology, cell culture, and analytical instruments. Overlaps with Spore.Bio's analytical instrument positioning in pharma and food QC.
  • Bio-Rad Laboratories: Established life science and clinical diagnostics company with a real-time PCR and digital PCR portfolio widely used for microbial detection in food, water, and pharma QC — competes with Louis's speed advantage.

Direct peers

  • Hygiena: Specializes in rapid microbiology and ATP hygiene monitoring for food safety and beverage manufacturing — direct overlap with Spore.Bio's food & beverage and environmental monitoring use cases.
  • R-Biopharm: Mid-cap German diagnostics company specializing in food and feed safety testing, including rapid microbiology and PCR-based pathogen detection — direct overlap in industrial food QC workflows.

Emerging players

  • Clear Labs: AI-driven food safety testing company using next-generation sequencing for pathogen detection in food production. Closest emerging competitor applying AI/computational biology to industrial microbial testing.

Others

  • Eurofins Scientific: World's largest food and pharmaceutical testing services network, operating centralized labs that perform conventional microbiology for manufacturers. Could be both a competitor (service-based testing) and a partner/distribution channel for Spore.Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Spore.Bio social profiles

Digital presence

Spore.Bio compliance and trust

Trust signal

Compliance2 records

Spore.Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spore.Bio leadership team

Management profile

Number of profiles

Profiles5 records

Spore.Bio funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spore.Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spore.Bio

What does Spore.Bio do?

Spore.Bio sells the Louis device, an AI-based microbiological detection instrument that detects, quantifies, and identifies living microorganisms in under 10 minutes without culture, enrichment, or dyes. The platform combines proprietary dual-wavelength illumination with a Transformer-based AI model to deliver reagent-free microbial testing for factory floors, supported by recurring single-use consumables and a 21 CFR Part 11 compliant cloud dashboard.

Is Spore.Bio a public or private company?

Spore.Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spore.Bio founded?

Spore.Bio was founded in 2023. It employs 51 to 100 people.

Where is Spore.Bio based?

Spore.Bio is headquartered in Paris, France, in the Europe region.

How does Spore.Bio make money?

Three revenue lines are on record. Louis Device Sales are the primary driver. The others are proprietary Consumables and cloud Dashboard & Data Services.

Who are Spore.Bio's main competitors?

Broad incumbents on record are bioMérieux, Neogen Corporation, Becton Dickinson (BD), Merck KGaA (MilliporeSigma), Thermo Fisher Scientific and Bio-Rad Laboratories. Direct peers are Hygiena and R-Biopharm. Clear Labs is listed as an emerging player. Eurofins Scientific is listed as an others.

Does Spore.Bio have an API?

No public API is recorded for Spore.Bio.

What industry is Spore.Bio in?

Spore.Bio's product category is Microbiology Testing Instruments. Its primary akta.pro industry code is HLAAALAG, Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Spore.Bio Names Dr. Michael J. Miller As VP To Bolster Scientific And Regulatory Strategy For Rapid MicrobiologySpore.Bio appointed Dr. Michael J. Miller as Vice President of Scientific and Regulatory Affairs, bringing nearly four decades of experience in pharmaceutical microbiology and contamination control. The company expects him to strengthen scientific positioning and regulatory engagement as it expands its on-site hardware and software stack. The appointment comes ahead of a planned March 24 announcement at industry conferences.blog.googleWe’re announcing the 12 recipients of our AI for Science fundGoogle.org announced twelve recipients of its $20 million AI for Science fund, which supports academic, nonprofit, and startup organizations using artificial intelligence to address complex scientific challenges in health, agriculture, and biodiversity. The funded organizations include UW Medicine, Cedars-Sinai Medical Center, Technical University of Munich, Makerere University's Infectious Disease Institute, Spore.Bio, The Sainsbury Laboratory, the Periodic Table of Food Initiative, the Innovative Genomics Institute at UC Berkeley, The Rockefeller University, UNEP-WCMC, the Swiss Plasma Center at EPFL, and the University of Liverpool. The initiative aims to produce open-source datasets and solutions, with Google.org committing to continue supporting organizations that drive breakthrough science.EU-StartupsFrench BioTech Spore.Bio secures multi-million-euro Google.org funding and launches AI-native research unitParis-based BioTech startup Spore.Bio has secured multi-million-euro funding from the Google.org AI for Science Fund and launched Spore.Labs, an AI-native research division focused on public health challenges using photonics and AI for microbiology testing. The company's technology enables on-site microbial testing in minutes, compared to traditional methods that take five to 20 days requiring off-site lab processing. Spore.Bio has raised €29.9 million to date, including a €22 million Series A led by Singular last year, and plans to hire 30 scientists by the end of 2026.MediumAI for so many things, and recent investments.This newsletter episode covers three AI startup funding rounds: UK-based Convergence Labs raised $12 million in pre-seed funding for its next-generation web search agent called Proxy, Cambridge-based Luminance secured $138 million for its AI-powered contract management platform for the legal industry, and Spore.bio received $32 million investment for its instant microbiological testing technology for food and cosmetics using AI models.FinSMEsSpore.Bio Raises $23M in Series A FundingSpore.Bio, a Paris-based AI-based bacteria detection startup, raised $23M in Series A funding led by Singular. The company will use the funds to double its workforce from 25 to 50 scientists and engineers and scale industrialization. It also secured an academic partnership with the Pasteur Institute and acquired competitor Greentropism.Tech.euSpore.Bio secures $23M Series A for on-site microbiology testingSpore.Bio raised $23 million in a Series A, bringing total funding to $31.3 million. The startup's on-site microbiology testing device uses machine learning to measure bacterial concentrations in food, beverages, pharmaceuticals, and cosmetics. It plans to double its workforce to 50 by 2025.FRENCHWEB.FRSécurité alimentaire : Spore.Bio lève 22 millions d’euros pour une détection instantanée des contaminantsSpore.Bio raised €22 million in a Series A led by Singular to accelerate its instant microbial detection technology. The startup, founded in 2023, has over 200 factories waiting to adopt its AI and photonics-based solution. It plans to double its workforce to 50 researchers and engineers and launch commercially by end of 2025.SiliconANGLESpore.Bio raises $23M to cut microbiology testing to minutes from days using AI - SiliconANGLESpore.Bio raised $23 million in a Series A led by Singular to accelerate microbiology testing. The Paris-based startup's AI-based method detects pathogens in minutes, cutting from days, and plans to roll out to about 200 factories by end of 2025.TechCrunchSpore.Bio raises $23M to apply machine learning to microbiology testingSpore.Bio, a Paris-based deeptech startup, raised $23 million in a Series A led by Singular. The company uses machine learning to detect bacteria in food samples, cutting testing time from days to minutes. It plans to expand its team to 50 by end of 2025.LinkedInExcited to welcome Spore.Bio to the LocalGlobe family! From Paris, this deeptech tech startup is building the world’s first real-time pathogen detection device for factories - reducing the sampling…LocalGlobe has led the pre-seed funding round for Spore.Bio, a Paris-based deeptech startup developing real-time pathogen detection devices for factory environments. The technology reduces bacterial detection time from 20 days to minutes by enabling on-site analysis using AI. This investment supports the founding team in scaling their scientific and engineering capabilities.